Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Descriptor ID |
D003550
|
| MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
| Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 3 | 1 | 4 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 2 | 7 | | 2002 | 12 | 0 | 12 | | 2003 | 8 | 0 | 8 | | 2004 | 13 | 0 | 13 | | 2005 | 15 | 4 | 19 | | 2006 | 13 | 3 | 16 | | 2007 | 22 | 1 | 23 | | 2008 | 13 | 3 | 16 | | 2009 | 18 | 1 | 19 | | 2010 | 21 | 3 | 24 | | 2011 | 14 | 1 | 15 | | 2012 | 19 | 1 | 20 | | 2013 | 3 | 2 | 5 | | 2014 | 21 | 3 | 24 | | 2015 | 26 | 0 | 26 | | 2016 | 29 | 1 | 30 | | 2017 | 24 | 1 | 25 | | 2018 | 30 | 4 | 34 | | 2019 | 35 | 1 | 36 | | 2020 | 44 | 0 | 44 | | 2021 | 53 | 2 | 55 | | 2022 | 55 | 0 | 55 | | 2023 | 61 | 0 | 61 | | 2024 | 34 | 4 | 38 | | 2025 | 42 | 0 | 42 | | 2026 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Zemanick ET, Somayaji R. Clearing the Air: Rethinking Airway Infection With CFTR Modulators. J Infect Dis. 2026 04 29; 233(4):628-630.
-
Zaretsky MV, Blumenfeld YJ, Szentpetery SS, Taylor-Cousar JL. Translating Emerging Data for Fetal Treatment of Cystic Fibrosis. Prenat Diagn. 2026 Mar; 46(3):417-423.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 Feb 01; 23(2):241-251.
-
Liu CM, Fischer JL, Overdevest JB, Zemke AC, Strand MJ, Gudis DA, Kimple AJ, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Taylor-Cousar JL, Beswick DM. Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis. J Cyst Fibros. 2026 Mar; 25(2):353-358.
-
Burke A, Jahnke N, Smith S, Smyth AR, Stewart I, Tillman L, Nick JA. Non-antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis - A systematic review. J Cyst Fibros. 2026 Mar; 25(2):248-256.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, C Ling S, Paranjape SM, Karnsakul W, Jay Freeman A, Schwarzenberg SJ, Palermo J, Alonso E, Green N, Masand P, Karmazyn B, Harned R, Navarro OM, Siegel MJ, Towbin A, Alazraki A, Otto RK, Nicholas JL, Narkewicz MR. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat Commun. 2025 Nov 18; 16(1):10111.
-
Jin X, Juarez-Colunga E, Buuren SV, Colborn K, Rosenfeld M, Graber J, Stevens-Lapsley J. A personalized prediction of longitudinal growth using People-Like-Me methods. Comput Biol Med. 2025 Dec; 199:111281.
-
Vladar EK, Gillen AE, Yadav S, Murphree MR, Baraghoshi D, Harris JK, Pruesse E, Niemiec SS, Wilson AW, Hisert KB, Humphries SM, Strand M, Lynch DA, Seibold MA, Beswick DM, Taylor-Cousar JL. Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy. JCI Insight. 2025 Nov 10; 10(21).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|